Literature DB >> 21130299

Glucosamine attenuates increases of intraabdominal fat, serum leptin levels, and insulin resistance induced by a high-fat diet in rats.

Cornelio Barrientos1, Radu Racotta, Lucía Quevedo.   

Abstract

The levels of circulating nonesterified fatty acids increase during obesity and contribute to insulin resistance by inhibiting insulin-stimulated glucose transport and phosphorylation in human muscles. In cells, glucose-6-phosphate is primarily used in glycogenesis and glycolysis; only 1% to 3% is converted to glucosamine-6-phosphate, which enters the hexosamine-biosynthesis pathway. The major end product of this pathway, uridine-5'-diphosphate-N-acetyl-glucosamine, which is increased by exogenous glucosamine (GlcN) administration, mediates insulin resistance. We hypothesized that the administration of GlcN to rats receiving a high-fat (HF) diet may potentiate the effects of an HF diet on glucose tolerance and other metabolic variables. To evaluate this relationship, 2 groups of rats were fed with a control or HF diet; and another 2 groups received glucosamine hydrochloride at a dose of 500 mg/kg dissolved in drinking water for 21 weeks. Metabolic variables related to insulin resistance were then measured. The levels of blood glucose and serum insulin were higher in a glucose tolerance test in the HF group as compared with the control group. Rats receiving GlcN had reduced liver glycogen and only slightly worsened glucose tolerance as compared with control rats, although this did not induce insulin resistance as evaluated by the homeostasis model assessment. Glucosamine administration was able to partially or completely inhibit some effects of the HF diet by reducing fat depot weight and serum leptin levels, thus resulting in a smaller increase in the insulinemic response to a glucose injection and lower postabsorptive glycemia.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21130299     DOI: 10.1016/j.nutres.2010.10.008

Source DB:  PubMed          Journal:  Nutr Res        ISSN: 0271-5317            Impact factor:   3.315


  6 in total

1.  Ameliorative Effects of Oral Glucosamine on Insulin Resistance and Pancreatic Tissue Damage in Experimental Wistar rats on a High-fat Diet.

Authors:  Cornelio Barrientos; Angélica Pérez; Jorge Vázquez
Journal:  Comp Med       Date:  2021-06-03       Impact factor: 0.982

2.  Glycolytic inhibition: an effective strategy for developing calorie restriction mimetics.

Authors:  Donald K Ingram; George S Roth
Journal:  Geroscience       Date:  2020-11-12       Impact factor: 7.713

3.  OGT suppresses S6K1-mediated macrophage inflammation and metabolic disturbance.

Authors:  Yunfan Yang; Xiruo Li; Harding H Luan; Bichen Zhang; Kaisi Zhang; Jin Hyun Nam; Zongyu Li; Minnie Fu; Alexander Munk; Dongyan Zhang; Simeng Wang; Yuyang Liu; João Paulo Albuquerque; Qunxiang Ong; Rui Li; Qi Wang; Marie E Robert; Rachel J Perry; Dongjun Chung; Gerald I Shulman; Xiaoyong Yang
Journal:  Proc Natl Acad Sci U S A       Date:  2020-06-29       Impact factor: 11.205

4.  The long-term ingestion of a diet high in extra virgin olive oil produces obesity and insulin resistance but protects endothelial function in rats: a preliminary study.

Authors:  Hady Keita; Eduardo Ramírez-San Juan; Norma Paniagua-Castro; Leticia Garduño-Siciliano; Lucía Quevedo
Journal:  Diabetol Metab Syndr       Date:  2013-09-18       Impact factor: 3.320

5.  Undaria pinnatifida and Fucoxanthin Ameliorate Lipogenesis and Markers of Both Inflammation and Cardiovascular Dysfunction in an Animal Model of Diet-Induced Obesity.

Authors:  Ameyalli Grasa-López; Ángel Miliar-García; Lucía Quevedo-Corona; Norma Paniagua-Castro; Gerardo Escalona-Cardoso; Elba Reyes-Maldonado; María-Eugenia Jaramillo-Flores
Journal:  Mar Drugs       Date:  2016-08-03       Impact factor: 5.118

6.  Glucosamine prevents polarization of cytotoxic granules in NK-92 cells by disturbing FOXO1/ERK/paxillin phosphorylation.

Authors:  Janja Božič; Veronika Stoka; Iztok Dolenc
Journal:  PLoS One       Date:  2018-07-17       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.